ID   SU2
AC   CVCL_RQ44
SY   SU-2
DR   Wikidata; Q54970756
RX   PubMed=18940013;
RX   PubMed=22360855;
CC   Group: Cancer stem cell line.
CC   Population: Chinese.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Brain, right temporal lobe; UBERON=UBERON_0002809.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_RQ43 ! SU1
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 7
//
RX   PubMed=18940013; DOI=10.1186/1471-2407-8-304; PMCID=PMC2584338;
RA   Huang, Qiang
RA   Zhang, Quan-Bin
RA   Dong, Jun
RA   Wu, Yin-Yan
RA   Shen, Yun-Tian
RA   Zhao, Yao-Dong
RA   Zhu, Yu-De
RA   Diao, Yi
RA   Wang, Ai-Dong
RA   Lan, Qing
RT   "Glioma stem cells are more aggressive in recurrent tumors with
RT   malignant progression than in the primary tumor, and both can be
RT   maintained long-term in vitro.";
RL   BMC Cancer 8:304.1-304.11(2008).
//
RX   PubMed=22360855; DOI=10.5732/cjc.011.10336; PMCID=PMC3777477;
RA   Wan, Yi
RA   Fei, Xi-Feng
RA   Wang, Zhi-Min
RA   Jiang, Dong-Yi
RA   Chen, Han-Chun
RA   Yang, Jian
RA   Shi, Lei
RA   Huang, Qiang
RT   "Expression of miR-125b in the new, highly invasive glioma stem cell
RT   and progenitor cell line SU3.";
RL   Chin. J. Cancer 31:207-214(2012).
//